- Nachrichtendetail
-
01.05.2024 12:30:27 - dpa-AFX: EQS-News: Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update (english)
Immunic, Inc. to Announce Financial Results for the First Quarter Ended
March 31, 2024, and Provide Corporate Update
Issuer: Immunic AG / Key word(s): Miscellaneous
Immunic, Inc. to Announce Financial Results for the First Quarter Ended
March 31, 2024, and Provide Corporate Update
01.05.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Immunic, Inc. to Announce Financial Results for the First Quarter Ended
March 31, 2024, and Provide Corporate Update
- Webcast to be Held at 8:00 am ET on May 8, 2024 -
NEW YORK, May 1, 2024 - Immunic, Inc. (Nasdaq: IMUX), a biotechnology
company developing a clinical pipeline of orally administered, small
molecule therapies for chronic inflammatory and autoimmune diseases, today
announced that the company will release its financial results for the first
quarter ended March 31, 2024, including a corporate update, on Wednesday,
May 8, 2024, before the opening of the U.S. financial markets. A webcast
will follow at 8:00 am ET.
To participate in the webcast, please register in advance at:
https://imux.zoom.us/webinar/register/WN_K6jgjaMURFiJjgA5i9-M8g or on the
"Events and Presentations" section of Immunic's website at:
ir.imux.com/events-and-presentations. Registrants will receive a
confirmation email containing a link for online participation or a telephone
number for dial in access.
An archived replay of the webcast will be available approximately one hour
after completion on Immunic's website at:
ir.imux.com/events-and-presentations.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a
clinical pipeline of orally administered, small molecule therapies for
chronic inflammatory and autoimmune diseases. The company's lead development
program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2
clinical trials for the treatment of relapsing and progressive multiple
sclerosis, respectively, and has shown therapeutic activity in phase 2
clinical trials in patients suffering from relapsing-remitting multiple
sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative
colitis. Vidofludimus calcium combines neuroprotective effects, through its
mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator,
with additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which
targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal
barrier function and regenerate bowel epithelium, which could potentially be
applicable in numerous gastrointestinal diseases, such as celiac disease,
for which it is currently in preparations for a phase 2 clinical trial.
IMU-381, which currently is in preclinical testing, is a next generation
molecule being developed to specifically address the needs of
gastrointestinal diseases. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve
substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press release
regarding strategy, future operations, future financial position, future
revenue, projected expenses, sufficiency of cash and cash runway, expected
timing, development and results of clinical trials, prospects, plans and
objectives of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to Immunic's
development programs and the targeted diseases; the potential for Immunic's
development programs to safely and effectively target diseases; preclinical
and clinical data for Immunic's development programs; the timing of current
and future clinical trials and anticipated clinical milestones; the nature,
strategy and focus of the company and further updates with respect thereto;
the development and commercial potential of any product candidates of the
company; and the company's expected cash runway. Immunic may not actually
achieve the plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements and you should not
place undue reliance on these forward-looking statements. Such statements
are based on management's current expectations and involve substantial risks
and uncertainties. Actual results and performance could differ materially
from those projected in the forward-looking statements as a result of many
factors, including, without limitation, the COVID-19 pandemic, increasing
inflation, impacts of the Ukraine - Russia conflict and the conflict in the
Middle East on planned and ongoing clinical trials, risks and uncertainties
associated with the ability to project future cash utilization and reserves
needed for contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet business
objectives and operational requirements, the fact that the results of
earlier preclinical studies and clinical trials may not be predictive of
future clinical trial results, the protection and market exclusivity
provided by Immunic's intellectual property, risks related to the drug
development and the regulatory approval process and the impact of
competitive products and technological changes. A further list and
descriptions of these risks, uncertainties and other factors can be found in
the section captioned "Risk Factors," in the company's Annual Report on Form
10-K for the fiscal year ended December 31, 2023, filed with the SEC on
February 22, 2024, and in the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available
online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this release.
Immunic disclaims any intent or obligation to update these forward-looking
statements to reflect events or circumstances that exist after the date on
which they were made. Immunic expressly disclaims all liability in respect
to actions taken or not taken based on any or all the contents of this press
release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
---------------------------------------------------------------------------
Dissemination of a Corporate News, transmitted by EQS News - a service of
EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
March 31, 2024, and Provide Corporate Update
Issuer: Immunic AG / Key word(s): Miscellaneous
Immunic, Inc. to Announce Financial Results for the First Quarter Ended
March 31, 2024, and Provide Corporate Update
01.05.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Immunic, Inc. to Announce Financial Results for the First Quarter Ended
March 31, 2024, and Provide Corporate Update
- Webcast to be Held at 8:00 am ET on May 8, 2024 -
NEW YORK, May 1, 2024 - Immunic, Inc. (Nasdaq: IMUX), a biotechnology
company developing a clinical pipeline of orally administered, small
molecule therapies for chronic inflammatory and autoimmune diseases, today
announced that the company will release its financial results for the first
quarter ended March 31, 2024, including a corporate update, on Wednesday,
May 8, 2024, before the opening of the U.S. financial markets. A webcast
will follow at 8:00 am ET.
To participate in the webcast, please register in advance at:
https://imux.zoom.us/webinar/register/WN_K6jgjaMURFiJjgA5i9-M8g or on the
"Events and Presentations" section of Immunic's website at:
ir.imux.com/events-and-presentations. Registrants will receive a
confirmation email containing a link for online participation or a telephone
number for dial in access.
An archived replay of the webcast will be available approximately one hour
after completion on Immunic's website at:
ir.imux.com/events-and-presentations.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a
clinical pipeline of orally administered, small molecule therapies for
chronic inflammatory and autoimmune diseases. The company's lead development
program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2
clinical trials for the treatment of relapsing and progressive multiple
sclerosis, respectively, and has shown therapeutic activity in phase 2
clinical trials in patients suffering from relapsing-remitting multiple
sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative
colitis. Vidofludimus calcium combines neuroprotective effects, through its
mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator,
with additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which
targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal
barrier function and regenerate bowel epithelium, which could potentially be
applicable in numerous gastrointestinal diseases, such as celiac disease,
for which it is currently in preparations for a phase 2 clinical trial.
IMU-381, which currently is in preclinical testing, is a next generation
molecule being developed to specifically address the needs of
gastrointestinal diseases. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve
substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press release
regarding strategy, future operations, future financial position, future
revenue, projected expenses, sufficiency of cash and cash runway, expected
timing, development and results of clinical trials, prospects, plans and
objectives of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to Immunic's
development programs and the targeted diseases; the potential for Immunic's
development programs to safely and effectively target diseases; preclinical
and clinical data for Immunic's development programs; the timing of current
and future clinical trials and anticipated clinical milestones; the nature,
strategy and focus of the company and further updates with respect thereto;
the development and commercial potential of any product candidates of the
company; and the company's expected cash runway. Immunic may not actually
achieve the plans, carry out the intentions or meet the expectations or
projections disclosed in the forward-looking statements and you should not
place undue reliance on these forward-looking statements. Such statements
are based on management's current expectations and involve substantial risks
and uncertainties. Actual results and performance could differ materially
from those projected in the forward-looking statements as a result of many
factors, including, without limitation, the COVID-19 pandemic, increasing
inflation, impacts of the Ukraine - Russia conflict and the conflict in the
Middle East on planned and ongoing clinical trials, risks and uncertainties
associated with the ability to project future cash utilization and reserves
needed for contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet business
objectives and operational requirements, the fact that the results of
earlier preclinical studies and clinical trials may not be predictive of
future clinical trial results, the protection and market exclusivity
provided by Immunic's intellectual property, risks related to the drug
development and the regulatory approval process and the impact of
competitive products and technological changes. A further list and
descriptions of these risks, uncertainties and other factors can be found in
the section captioned "Risk Factors," in the company's Annual Report on Form
10-K for the fiscal year ended December 31, 2023, filed with the SEC on
February 22, 2024, and in the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are available
online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking
statement made in this release speaks only as of the date of this release.
Immunic disclaims any intent or obligation to update these forward-looking
statements to reflect events or circumstances that exist after the date on
which they were made. Immunic expressly disclaims all liability in respect
to actions taken or not taken based on any or all the contents of this press
release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
---------------------------------------------------------------------------
Dissemination of a Corporate News, transmitted by EQS News - a service of
EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
